|Genomic Health, Inc. Announces Positive Preliminary Breast Cancer Results. Oncothyreon Inc. Advances To Phase 2 Portion of PX-866.|
|By BioMedReports.com Staff|
|Tuesday, 24 May 2011 18:59|
Positive preliminary results from a study of Oncotype DX in patients with DCIS (ductal carcinoma in situ of the breast) was announced by Genomic Health, Inc. (NASDAQ:GHDX) which conducted the Eastern Cooperative Oncology Group (ECOG), a clinical trials cooperative group supported by the National Cancer Institute.
ECOG and Genomic Health plan to submit complete data from this study for presentation at the 2011 San Antonio Breast Cancer Symposium in December. The ECOG 5194 validation study met its primary endpoint by demonstrating that a pre-specified Oncotype DX DCIS Score can predict the risk of local recurrence, defined as either the development of a new invasive breast cancer or the recurrence of DCIS in the same breast. Based on these positive findings, Genomic Health plans to make the Oncotype DX DCIS Score available to patients and physicians worldwide by year end.
Following successful completion of the Phase 1 dose escalation portion, Oncothyreon Inc. (NASDAQ:ONTY), has initiated the Phase 2 portion of its ongoing Phase 1/2 trial of PX-866 in combination with the chimeric monoclonal antibody cetuximab (Erbitux).
The primary objective of the Phase 1 portion of the trial was to determine the maximum tolerated or recommended daily dose of PX-866 to be given in combination with the standard dose of cetuximab administered weekly to patients with either progressive metastatic colorectal carcinoma (CRC) or progressive, recurrent or metastatic squamous cell carcinoma of the head and neck (SCCHN).
Preliminary results indicated PX-866 to be safe and well-tolerated in this trial. The Phase 2 portion is an open-label, randomized evaluation of the antitumor activity and safety of PX-866 administered at the recommended daily dose in combination with cetuximab, versus cetuximab alone, in two groups of patients not previously treated with cetuximab.
Bio-AMD, Inc. (OTCBB: BIAD) notes the announcement below made today by its 77% owned subsidiary, WDX Organisation Ltd ("WDX").
BioMedical Technology Solutions Holdings, Inc. ("BMTS") (OTCBB: BMTL) is pleased to announce that it has completed its fourth sale to medical equipment distributor ZAO NPP "MEDINTECH-M" in Moscow, Russia.
CDEX (OTCBB: CEXI) (www.cdex-inc.com), a leading developer of chemical detection products, using patented technologies, for use in healthcare and security markets, announced today the company was one of only 15 companies invited to participate at the Amerinet Niche Technology & Supplier Diversity Fair held May 12, 2011 in Orlando, Fla.
Cytori Therapeutics (NASDAQ: CYTX) will present and provide a corporate update from the Jefferies 2011 Global Healthcare Conference on Wednesday, June 8, 2011 at 8:00 AM ET.
TheDirectory.com, Inc. (PINKSHEETS: EYSM) an emerging leader in the Local Business Search Market , today announced that it has completed its name change from Elysium Internet, Inc. to TheDirectory.com, Inc. and authorized share reduction with the state of Utah.
D. Medical Industries Ltd. (NASDAQ:DMED) (TASE:DMED) ("D. Medical"), a medical device company engaged through its subsidiaries in the research, development, manufacture and sale of innovative products for diabetes treatment and drug delivery, today announced the execution of an agreement for the distribution of its Spring™ Universal Infusion Sets in Poland.
First China Pharmaceutical Group, Inc. (OTCBB: FCPG) ("First China" or the "Company") a rapidly growing and technologically advanced healthcare products distributor based in Yunnan, China is pleased to announce that as part of a recently completed round of capital financing, the Company has increased its investment efforts towards the implementation of a program of enhancements to its key online ordering and fulfillment system.
IntelGenx Technologies Corp. (TSX VENTURE:IGX) (OTCBB:IGXT) ("IntelGenx"), is pleased to announce that Dr. Rajiv Khosla has agreed to join IntelGenx' Board of Directors.
MMRGlobal, Inc. (OTCBB: MMRF) (www.mymedicalrecords.com), the leading provider of Personal Health Records, MyEsafeDepositBox storage solutions and electronic document management systems for consumers and healthcare professionals, announced today that The RHL Group, Inc., a corporation owned by Robert H. Lorsch, the Chairman, President and Chief Executive Officer of MMRGlobal and one of the Company's largest shareholders, has agreed to renew MMR's current three million dollar credit line.
Omeros Corporation (NASDAQ:OMER) today reported the allowance by the US Patent and Trademark Office (USPTO) of an additional patent claiming the composition of OMS103HP, the Company's arthroscopic PharmacoSurgery™ product in Phase 3 clinical development.
Pacira Pharmaceuticals, Inc. (Nasdaq:PCRX), an emerging specialty pharmaceutical company, today announced that Gary Patou, M.D., chief medical officer, is scheduled to present at the UBS Global Specialty Pharmaceuticals Conference being held in London on Wednesday, May 25, 2011 at noon BST. Dr. Patou is expected to present an overview of the company.
Phototron Holdings, Inc. (OTCQB: PHOT) (OTCBB: PHOT), the designer, manufacturer and seller of the PHOTOTRON Hydroponic Indoor Grow Systems, today announced that its Board of Directors has appointed Douglas Braun as Chief Executive Officer of the company.
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development-stage oncology and dermatology biopharmaceutical company, has completed patient accrual in its Phase 2C clinical trial of PH-10 for the treatment of psoriasis.
The Pulse Beverage Corporation (OTCBB: PLSB) ("Pulse" or the "Company"), makers of the PULSE® brand of "good-for-you" NutriPurpose™ beverages and Cabana™ all natural and reduced calorie lemonades, announced today that NBT Equity Research LLC has released a research report on the Company.
Savanna East Africa, Inc. (PINKSHEETS: NVAE) (OTCQB: NVAE) today announced a senior management and key stakeholders meeting scheduled in Nairobi the week of June 13th intended to finalize a number of strategic next steps.
Science Applications International Corporation (SAIC) (NYSE:SAI) announced today the appointment of Dr. David Heimbrook as chief executive officer of SAIC-Frederick, Inc., a wholly owned subsidiary of SAIC, effective May 31.
Spherix Incorporated (NASDAQ: SPEXD) – an innovator in biotechnology for therapy in diabetes, metabolic syndrome and atherosclerosis, and providers of technical and regulatory consulting services to food, supplement, biotechnology and pharmaceutical companies – today announced that it has regained compliance with NASDAQ listing rule 5550(a)(2), which concerns minimum bid price listing requirements.